Page last updated: 2024-11-01

niceritrol and Cardiovascular Stroke

niceritrol has been researched along with Cardiovascular Stroke in 1 studies

Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.

Research Excerpts

ExcerptRelevanceReference
"Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids, especially oleate (18 : 1), in the cholesterol esters, triglycerides and phospholipids while there were significant reductions of the content of linoleic (18 : 2) acid in both the cholesterol esters and triglycerides."2.65Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol. ( Boberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1980)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vessby, B1
Lithell, H1
Gustafsson, IB1
Boberg, J1

Trials

1 trial available for niceritrol and Cardiovascular Stroke

ArticleYear
Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
    Atherosclerosis, 1980, Volume: 35, Issue:1

    Topics: Aged; Cholesterol Esters; Clinical Trials as Topic; Clofibrate; Diet Therapy; Dose-Response Relation

1980